Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide

被引：14
|
作者：
Montagut, C [1 ]
Bosch, F [1 ]
Villela, L [1 ]
Rosiñol, L [1 ]
Bladé, J [1 ]
机构：
[1] Univ Barcelona, Hosp Clin, IDIBAPS, ICMHO,Dept Hematol, E-08036 Barcelona, Spain
来源：
LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 08期
关键词：
multiple myeloma; thalidomide; aminoglycoside; renal failure;
D O I：
10.1080/10428190310001638841
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thalidomide has been proved to play an important role in rescue treatment of patients with refractory/relapsed multiple myeloma (MM). However, thalidomide therapy is associated with numerous side effects, mainly somnolence, constipation, fatigue or peripheral neuropathy. We report three patients diagnosed with MM and treated with thalidomide as salvage therapy who developed severe renal failure when they received aminoglycoside antibiotics. This observation suggests that thalidomide can potentiate nephrotoxicity of aminoglycoside antibiotics in patients with MM.
引用
收藏
页码：1711 / 1712
页数：2
相关论文
共 50 条
  • [1] Thalidomide in patients with multiple myeloma and renal failure
    Fakhouri, F
    Guerraoui, H
    Presne, C
    Peltier, J
    Delarue, R
    Muret, P
    Knebelmann, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 96 - 97
  • [2] Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia
    Harris, E
    Behrens, J
    Samson, D
    Rahemtulla, A
    Russell, NH
    Byrne, JL
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) : 160 - 161
  • [3] CHEMOTHERAPY OF THE PATIENTS WITH MULTIPLE MYELOMA AGGRAVATED BY SEVERE RENAL FAILURE
    Rekhtina, I. G.
    Biryukova, L. S.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2010, 55 (06): : 9 - 13
  • [4] Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy
    James Wang
    Kyle A. Udd
    Aleksandra Vidisheva
    Regina A. Swift
    Tanya M. Spektor
    Eric Bravin
    Emad Ibrahim
    Jonathan Treisman
    Mohammed Masri
    James R. Berenson
    Supportive Care in Cancer, 2016, 24 : 3105 - 3110
  • [5] Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
    Tosi, P
    Zamagni, E
    Cellini, C
    Cangini, D
    Tacchetti, P
    Tura, S
    Baccarani, M
    Cavo, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (02) : 98 - 103
  • [6] Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy
    Wang, James
    Udd, Kyle A.
    Vidisheva, Aleksandra
    Swift, Regina A.
    Spektor, Tanya M.
    Bravin, Eric
    Ibrahim, Emad
    Treisman, Jonathan
    Masri, Mohammed
    Berenson, James R.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (07) : 3105 - 3110
  • [7] Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
    Castro, T. B. M.
    Hallack Neto, A. E.
    Atalla, A.
    Ribeiro, L. C.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (06) : e5128
  • [8] In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide
    Petropoulou, Anna D.
    Gerotziafas, Grigoris T.
    Samama, Meyer M.
    Hatmi, Mohamed
    Rendu, Francine
    Elalamy, Ismail
    THROMBOSIS RESEARCH, 2008, 121 (04) : 493 - 497
  • [9] Thalidomide and thrombosis in patients with multiple myeloma
    Camba, L
    Peccatori, J
    Pescarollo, A
    Tresoldi, M
    Corradini, P
    Bregni, M
    HAEMATOLOGICA, 2001, 86 (10) : 1108 - 1109
  • [10] Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure
    Moore, Donald C.
    Arnall, Justin R.
    Janes, Amanda
    Pineda-Roman, Mauricio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07) : E395 - E398
12345